Role of nuclear factor-κB in the immune system and bone

Immunological Reviews

Volumn 208, Issue , 2005, Pages 80-87

  Jimi, Eijiro ^a   Ghosh, Sankar ^b  

^a KYUSHU DENTAL COLLEGE   (Japan)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; I KAPPA B; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; SP 100030; UNCLASSIFIED DRUG;

ARTHRITIS; BONE; BONE DESTRUCTION; BONE DEVELOPMENT; BONE INFECTION; BONE METABOLISM; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; DISEASE COURSE; GENE TRANSFER; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; MICROENVIRONMENT; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 28544453229     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00329.x     Document Type: Review

References (58)

1. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004;18:2195-2224.
2. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-288.
3. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109 (Suppl.):S81-96.
4. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342.
5. Rho J, Takami M, Choi Y. Osteoimmunology: interactions of the immune and skeletal systems. Mol Cell 2004;17:1-9.
6. Walsh MC, Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev 2003;14:251-263.
7. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005;83:170-179.
8. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
9. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-κB in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995;38:1762-1770.
10. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-κB activity. J Immunol 2002;168:1441-1446.
11. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 1997;3:1285-1289.
12. Franzoso G, et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev 1997;11:3482-3496.
13. Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol 2002;2:725-734.
14. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science 2000;289:1550-1554.
15. Jimi E, et al. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004;10:617-624.
16. May MJ, Marienfeld RB, Ghosh S. Characterization of the IκB-kinase NEMO binding domain. J Biol Chem 2002;277:45992-46000.
17. Xiao G, Harhaj EW, Sun SC. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol Cell 2001;7:401-409.
18. Xiao G, Fong A, Sun SC. Induction of p100 processing by NF-κB-inducing kinase involves docking IκB kinase alpha (IKKα) to p100 and IKKα-mediated phosphorylation. J Biol Chem 2004;279:30099-30105.
19. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells. Nat Immunol 2002;3:958-965.
20. Coope HJ, et al. CD40 regulates the processing of NF-κB2 p100 to p52. EMBO J 2002;21:5375-5385.
21. Muller JR, Siebenlist U. Lymphotoxin beta receptor induces sequential activation of distinct NF-κB factors via separate signaling pathways. J Biol Chem 2003;278:12006-12012.
22. Chambers TJ, Thomson BM, Fuller K. Effect of substrate composition on bone resorption by rabbit osteoclasts. J Cell Sci 1984;70:61-71.
23. Baron R, Neff L, Louvard D, Courtoy PJ. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol 1985;101:2210-2222.
24. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357.
25. Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003;15:280-287.
26. Kong YY, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
27. Dougall WC, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-2424.
28. Hughes AE, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 2000;24:45-48.
29. Takayanagi H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901.
30. Matsuo K, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004;279:26475- 26480.
31. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF. Fos11 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 2000;24:184-187.
32. Ikeda F, et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004;114:475-484.
33. Ye H, et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 2002;418:443-447.
34. Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D, Dougall WC. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 2002;277:44347-44356.
35. Liu W, et al. Functional identification of three receptor activator of NF-κB cytoplasmic motifs mediating osteoclast differentiation and function. J Biol Chem 2004;279:54759-54769.
36. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB. Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase. J Biol Chem 1998;273:20551-20555.
37. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J Biol Chem 1998;273:28355-28359.
38. Naito A, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999;4:353-362.
39. Novack DV, et al. The IkappaB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J Exp Med 2003;198:771-781.
40. Cao Y, et al. IKKκ provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 2001;107:763-775.
41. Chaisson ML, et al. Osteoclast differentiation is impaired in the absence of inhibitor of κB kinase α. J Biol Chem 2004;279:54841-54848.
42. Kaisho T, et al. IκB kinase α is essential for mature B cell development and function. J Exp Med 2001;193:417-426.
43. Senftleben U, et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 2001;293:1495-1499.
44. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-361.
45. Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 1997;61:1861-1878.
46. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992;35:729-735.
47. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241-251.
48. Mauri C, Williams RO, Walmsley M, Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996;26:1511-1518.
49. Luross JA, Williams NA. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001;103:407-416.
50. Baldwin AS Jr. The NF-κB and I κB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-683.
51. Seetharaman R, Mora AL, Nabozny G, Boothby M, Chen J. Essential role of T cell NF-κB activation in collagen-induced arthritis. J Immunol 1999;163:1577-1583.
52. Gerlag DM, et al. The effect of a T cell-specific NF-κB inhibitor on in vitro cytokine production and collagen-induced arthritis. J Immunol 2000;165:1652-1658.
53. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum 1996;39:1781-1790.
54. Zvaifler NJ, Tsai V, Alsalameh S, von Kempis J, Firestein GS, Lotz M. Pannocytes: distinctive cells found in rheumatoid arthritis articular cartilage erosions. Am J Pathol 1997;150:1125-1138.
55. Yamasaki S, et al. Importance of NF-κB in rheumatoid synovial tissues: in situ NF-κB expression and in vitro study using cultured synovial cells. Ann Rheum Dis 2001;60:678-684.
56. Tak PP, et al. Inhibitor of nuclear factor κB kinase β is a key regulator of synovial inflammation. Arthritis Rheum 2001;44:1897-1907.
57. Miagkov AV, et al. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998;95:13859-13864.
58. Dai S, Hirayama T, Abbas S, Abu-Amer Y. The κB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 2004;279:37219-37222.